Long-term immune response to yellow fever vaccination in HIV-infected individuals depends on HIV-RNA suppression status: Implications for vaccination schedule. by Veit, Olivia Stephanie et al.
 © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of 
America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 
 
Long-term immune response to yellow fever vaccination in HIV-infected individuals depends on 
HIV-RNA suppression status: Implications for vaccination schedule 
 
Olivia Veit, MD
1,2
, Cristina Domingo, PhD
3
,
 
Matthias Niedrig, PhD
3
, Cornelia Staehelin, MD
1
, Beat 
Sonderegger, MD
1
, Delphine Héquet, MD
4
, Marcel Stoeckle, MD
5
, Alexandra Calmy, MD
6
, Veronique Schiffer, 
MD
6
, Enos Bernasconi, MD
7
, Domenica Flury, MD
8
, Christoph Hatz, MD
2,9,10
, Marcel Zwahlen, PhD
11*
, 
Hansjakob Furrer, MD
1*
, and the Swiss HIV Cohort Study
+
  
1
Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland  
2
Institute of Epidemiology, Biostatistics and Prevention, University of Zürich, Switzerland 
3
Robert Koch-Institut, Berlin, Germany 
4
Division of Infectious Diseases, University Hospital of Lausanne, Switzerland 
5
Division of Infectious Diseases, University Hospital of Basel, Switzerland 
6
Division of Infectious Diseases, University Hospital of Geneva, Switzerland 
7
Division of Infectious Diseases, Cantonal Hospital of Lugano, Switzerland 
8
Division of Infectious Diseases, Cantonal Hospital of St. Gallen, Switzerland 
9
Swiss Tropical and Public Health Institute Basel, Switzerland 
10
University of Basel, Switzerland 
11
Institute of Social and Preventive Medicine, University of Bern, Switzerland 
 
*contributed equally to the manuscript 
+Members listed at the end of the paper 
 
 
 
  
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix960/4616867
by E-Library Insel user
on 21 November 2017
    
 2 
Corresponding author: 
Olivia Veit, MD, MIH 
Department of Infectious Diseases 
Bern University Hospital  
CH-3010 Bern 
E-MAIL:  oveit@yahoo.com  
Phone:  +41 76 679 60 99 
Fax:  +41 31 632 31 76 
 
Running title: Yellow fever vaccine in HIV+ individuals 
 
Summary: HIV-infected patients' long-term immune response to yellow fever vaccination is primarily dependent 
on the control of HIV replication at the time of vaccination and is comparable to that of non-HIV-infected adults 
if successful antiretroviral therapy is not interrupted. 
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Abstract  
Background: In HIV-infected individuals the immune response over time to yellow fever vaccination (YFV) 
and the necessity for booster vaccination are not well understood. 
Methods: We studied 247 participants of the Swiss HIV Cohort Study (SHCS) with a first YFV after HIV 
diagnosis and determined their immune responses at one, five, and ten years postvaccination (p.v.) by yellow 
fever plaque reduction neutralisation titres (PRNT) in stored blood samples. A PRNT of 1:≥10 was regarded as 
reactive and protective. Predictors of vaccination response were analysed with Poisson regression.  
Results: At vaccination, 82% of the vaccinees were taking combination antiretroviral therapy (cART), 83% had 
suppressed HIV RNA levels (<400 copies/ml), and their median CD4 cell count was 536 cells/mm
3
. PRNT was 
reactive in 46% (95% CI 38%-53%) before, 95% (91%-98%) within one year, 86% (79%-92%) at five years, 
and 75% (62%-85%) at 10 years p.v. In those with suppressed plasma HIV RNA at YVF, the proportion with 
reactive PRNT remained high: 99% (95%-99.8%) within one year, 99% (92%-100%) at five years, and 100% 
(86%-100%) at ten years. 
Conclusions: HIV-infected patients' long-term immune response up to ten years to YFV is primarily dependent 
on the control of HIV replication at the time of vaccination. For those on successful cART, immune response up 
to ten years is comparable to that of non-HIV-infected adults. We recommend a single YFV booster after ten 
years for patients vaccinated on successful cART, while those vaccinated with uncontrolled HIV RNA may need 
an early booster. 
 
Keywords: Yellow fever vaccination, HIV-infection, short- and long-term immune response, HIV-infected 
patients, plaque reduction neutralisation test, antiretroviral therapy, HIV-RNA, CD4 count 
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Main text 
 
Introduction 
Many HIV-infected persons live in or travel to regions where yellow fever (YF) is endemic [1,2]. The life-
attenuated, 17D strain YF vaccine, with its short-term seroconversion rate of up to 99% in immune-competent 
individuals, is an effective preventive measure for this mosquito-borne, severe viral haemorrhagic disease that 
lacks antiviral therapy [1]. In 2013, the World Health Organization (WHO) revised its recommendation of YF 
vaccination (YFV) boosters every 10 years to a single primary vaccination for lifelong protection of immune-
competent vaccinees [1,3]. This recommendation is controversial as there is limited evidence for the life-long 
immune response to YFV in particular in travellers from non-YF endemic countries [4–7].  
YFV is only recommended for asymptomatic HIV-infected persons who have CD4 cell counts >200 cells/mm
3
 
because the live-attenuated YFV poses a risk of life-threatening viscerotropic and neurotropic disease [8]. 
Although the number of HIV-infected persons travelling to endemic areas has been rising in recent years [2], the 
limited data on YFV immunogenicity in HIV-infected persons we do have are inconsistent and mostly address 
short-term immune response [9–12]. If and when revaccination is needed is unclear, and in 2013 the WHO 
Strategic Advisory Group of Experts on Immunisation recommended studying the efficacy and safety of YFV in 
HIV-infected individuals [13]. 
The prospective data and stored plasma samples of the Swiss HIV Cohort Study (SHCS) collected since 1988 
allow long-term analyses of serologic immune response to YFV [14,15]. A previous SHCS study measuring 
immune response with any available plaque reduction neutralisation titre (PRNT) measurement between one and 
ten years postvaccination (p.v.) in 70 vaccinees after the last of one or more documented YFV pointed towards 
an impaired immune response over time (seropositivity rate of 77%) [15]. 
We used stored SHCS samples to measure the short- and long-term immune responses at defined times after first 
documented YFV in HIV-infected patients to evaluate whether and when a booster vaccination should be 
recommended. We also investigated possible predictors for an adequate immune response to YFV in HIV-
infected persons, and evaluated the safety of YFV. 
 
Methods 
Patients and Data Collection 
The prospective SHCS (www.shcs.ch) is a systematic longitudinal cohort based at seven centres, and affiliated 
hospitals and physicians in Switzerland. SHCS collects clinical and laboratory data from patients upon 
enrolment and at six monthly follow-up visits. Plasma samples are obtained and stored at -75° C. [14]. A 
questionnaire is also used to inquire inter alia about travel to tropical countries and, since 2009, about receipt of 
YFV. 
Six SHCS centres participating in this study and recorded information on YFV from participants with at least 
one SHCS follow-up visit between 01.01.1989 and 31.12.2013. We also included SHCS participants from our 
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previous YFV study [15] that was based on evaluating all SHCS patients of four centers with a history of travel 
to the tropics and who could have been missed by the SHCS variable on YFV only introduced in 2009.  
Patients were asked to provide all available vaccination cards to verify YFV dates, and for this we also checked 
local vaccination centre databases, documents, and medical charts. All local ethical committees have approved 
the SHCS and all participants gave written informed consent before enrolment. 
Participants over 18 years of age with a first documented dose of YFV following HIV diagnosis were included if 
verification of the date of YFV was possible by either i) a vaccination card or vaccination centre documentation 
(252 of 276 total vaccinations [91%]), ii) information in patient medical charts as reviewed by two individuals 
(13 vaccinations [5%]), or iii) information from our previous study [15] if precise information on the vaccine 
type (Stamaril
®
 or another) was known (11 vaccinations [4%]). Vaccinees in our previous study [15] who did not 
fulfil these criteria were not included. All YFV dates were included and classified as first, second, or third 
vaccination for each participant. Those who had been vaccinated less than one year before documented HIV 
diagnosis were classified as being HIV infected at vaccination unless HIV seroconversion within this year was 
documented.  
As possible predictors of protective immune response at first documented YFV (baseline) and p.v., we extracted 
the following from the SHCS database: age, sex, origin in a YF endemic country, CDC classification, hepatitis B 
or C coinfection, smoking habits (±180 days around vaccination), combination antiretroviral therapy (cART), 
CD4 nadir before first vaccination, the closest CD4 value around the time of YFV (±365 days), and HIV RNA 
(less than one year before YFV). HIV RNA <400 copies/mL was defined as suppressed HIV viral load. The 
SHCS database was checked for hospitalisations and death within 90 days following YFV. 
 
Evaluation of Immunogenicity  
SHCS plasma samples frozen and stored before and after YFV were retrieved from all centres and sent on dry 
ice to the Robert Koch Institute (RKI), Berlin, Germany. Samples were analysed at four intervals: i) before YFV 
from any time prior to vaccination; ii) one year, which covered the interval from 30 to 365 days p.v. for the 
short-term immune response; (iii) 5 years, which included samples assayed between 4 and 6 years p.v., and (iv) 
10 years, for sample assays between 9.5 and 11 years p.v.  
At RKI, all plasma samples were analysed twice and in two-fold dilutions (range, 1:5 to 1:>320) using a YF 
plaque reduction neutralisation test [16]. The plaques caused by lysis of infected cells were counted and the 90% 
PRNT was calculated. Serum from a healthy vaccinee with known titer was included as positive control in all 
assays to assure interassay reproducibility. PRNTs of 1:≥10 are defined as reactive or detectable, and those of 
1:<10 as nonreactive or undetectable PRNT [17]. PRNT of 1:≥10 is generally believed to be a serological 
surrogate for protection against wild-type YF virus [18]. Decreasing PRNT was modelled as log10 of the 
reciprocal neutralisation titre over time.  
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Statistical analysis 
We report the proportion and 95% confidence intervals of blood samples categorized as reactive. Univariable 
and multivariable Poisson regression models were used to analyse characteristics associated with reactive PRNT 
as a binary outcome within the first year and after five and ten years p.v. [19]. Linear regression was used for 
univariable and multivariable analysis of parameters associated with the value of PRNT. The multivariable 
regression models included CD4 cell count nadir before YFV, HIV RNA <400 copies/ml as a binary variable 
and CD4 cell count at time of YFV, age, sex, chronic hepatitis B/C, origin in a YF endemic country, and having 
nonreactive PRNT before first YFV. Smoking was not included in the multivariable analysis as information was 
often missing and smoking habits can change rapidly. Square-root CD4 cell counts values and log10 of the 
reciprocal neutralisation titre were implemented in the regression model. Analyses were conducted using 
STATA (version 13, College Station, Texas, USA). 
 
Role of funding source 
Study sponsors (Swiss National Science Foundation, SHCS project 701, SHCS research funding) had no role in 
study design, data collection, analysis, and interpretation, or writing of the report. 
 
 
Results 
 
Study population 
We identified 247 participants with at least one documented YFV after HIV diagnosis, 27 participants had 
received two, and two participants three YFV doses. More than half of the participants were from sub-Saharan 
Africa. Baseline characteristics and laboratory findings are listed in Table 1. At baseline, the majority of the 
patients were taking cART (82%), had suppressed HIV RNA (83%), and their median CD4 cell count was 536 
cells/mm
3
. Eleven patients had been vaccinated with CD4 cell count below 200 cells/mm
3
 (range 11-193). 
 
Short-term and long-term immune response  
Results of the immune response are summarized in Table 2. Plasma before vaccination was available for 182 of 
the 247 patients (74%), 201 patients at one year (81%), 122 patients at five years (49%), and 63 patients at ten 
years (26%). The proportions of patients with reactive PRNT at these intervals are shown in Figures 1 and 2a. A 
longitudinal PRNT determination at all times was possible for 33 participants (Figure S1). The proportions with 
reactive PRNT in this group were 30% (95% CI 16-49%) prevaccination, 91% (76%-98%) at one year, 94% 
(80%-99%) at five, and 82% (65%-93%) at ten years p.v. and were similar to the whole population. The 
magnitude of PRNT also dropped over time (Figures 3a and 3b).  
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Forty-six percent of the vaccinees had reactive PRNT at baseline. This was more likely for patients originating 
from a YF-endemic country (p=0.02). Figure 2b shows the vaccine response among the 99 vaccinees with 
nonreactive PRNT before the first YFV. The vaccine response among those with HIV RNA suppressed at 
baseline was above 95% at all times and is shown in Figure 2c, and for patients with suppressed HIV RNA and 
non-reactive PRNT at baseline in Figure 2d.  
In patients with unsuppressed HIV RNA at baseline, reactive PRNT was found in 83% (29/35, 95% CI 66%-
93%) within one year, 83% (20/24, 63%-95%) at five, and 43%, (6/14, 18%-71%) at ten years p.v. The 
proportions were even lower in patients with nonreactive PRNT and unsuppressed HIV RNA at baseline. The 16 
patients with nonreactive PRNT at ten-year follow-up had been vaccinated between 1986-2003 and in none with 
available viral load data (n=8) was HIV RNA suppressed at baseline. 
 
Association of baseline parameters with immune response  
Suppressed HIV RNA at baseline was associated with reactive PRNT at one year, five and ten years with the 
strongest association at ten years (relative proportion = 2.1 (95% CI 1.2-3.6). Vaccinees with nonreactive PRNT 
at baseline had a lower, and those originating from an YF-endemic country had a higher probability of reactive 
PRNT within one year after vaccination but not thereafter (Tables 3a-c). In a multivariable subanalysis in 95 
patients who had nonreactive PRNT at baseline, no significant association was seen between patients originating 
from a YF-endemic country and reactive PRNT at one year p.v. (p= 0.08., data not shown). Suppressed HIV 
RNA at baseline was also the strongest predictor of the magnitude of immune response to YFV at one, five, and 
ten years p.v. (Tables S1a-c). 
A more than 3-fold PRNT increase to more than 1:90 we saw in four patients from one to five years and in four 
patients from five to ten years p.v. For these vaccinees we could not identify a booster YFV. 
 
Safety 
Two patients were hospitalised 55 and 90 days after vaccination but did not fulfil the case definition of suspected 
viscera- or neurologic disease [8,20]. Sixty of 247 vaccinees (24%) had received YFV before SHCS registration 
including 9 of 11 patients who received YFV with CD4 cell count below 200 cells/mm
3
 at baseline. These 
eleven patients are characterized in Table S2 and a reactive PRNT was seen for 5 of 7 at one year, for 2 of 8 at 
five years, and for 3 of 5 at ten years p.v. 
 
Discussion 
Persons infected with HIV demonstrated good short-term immune response to YFV of 95%, which decreased to 
75% ten years p.v. The long-term immune response of patients with HIV RNA suppressed at vaccination 
remained unimpaired for up to ten years.  
Participants’ short-term immune response within one year of vaccination was slightly impaired compared to the 
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reported seroconversion rate of up to 99% within 30 days in HIV-negative persons [1], but higher than 
previously reported in our cohort [15]. This is likely due to a higher proportion of patients on successful cART at 
baseline who showed a response of 99-100%, but could also be partly due to a high proportion of patients with 
reactive PRNT before first documented YFV. A French study also found a PRNT 1:≥10 in 44 of 45 HIV-
infected vaccinees (98%) [10], and in a YF endemic country 76 of 83 HIV-infected patients (92%) responded to 
YFV [12]. Other small series have shown similar results [9,11,21] with the exception of one study with 
seroprotection of only 17% in HIV-infected children in Côte d’Ivoire where problems with vaccine storage 
and/or administration were suspected [22].  
The longer term immune response to YFV decreased in our whole population from 95% at one year p.v. to 86% 
at five and 75% at ten years, while the respective proportions with reactive PRNT in patients with suppressed 
HIV RNA remained high. Quantitative antibody titres were also higher at all times in patients with plasma HIV 
RNA suppressed at baseline, although titres decreased over time (Figure 3a). A decrease of the proportion of 
reactive PRNTs similar to the one observed in our total population was reported in immune-competent vaccinees 
in a Brazilian study, with a gradual decrease of PRNT from 94% at 1-4 years to 83% at 5-9 and 76% at 10-11 
years [5]. In our patients with suppressed HIV replication, the long-term results up to ten years are similar to 
those of a general population reported in a recent systematic review that estimated a seropositivity rate at ≥10 
years p.v. of 92% (95% CI 85%-96%) [23].  
Data on the long-term immunity to primary YFV among HIV-infected persons are scarce. In a recent small 
series, 7 of 13 and then 4 of 8 patients had protective titres after a follow-up of five and ten years respectively 
[24]. Pacanowski et al. observed seropositivity in 66 of 72 French HIV-infected travellers (92%) with PRNT 
determination >10 years p.v.[10]—a result closer to our observation in patients with suppressed viremia at 
baseline. Fifty-seven of the 72 French patients had been vaccinated before HIV infection was diagnosed and 
those with booster vaccinations appear to have been included. Both could have positively influenced the immune 
response. The decrease we observed in quantitative PRNT over time was similar to that reported by Pacanowski 
et al. and a small Brazilian study [10,24]. 
Although we carefully tried to retrieve all previous YFV dates, more than 40% of patients were found to have 
reactive PRNT before first documented YFV, which indicates either prior YFV or past exposure to wild-type YF 
virus or, less likely, other flaviviruses. It is not possible to differentiate whether PRNT 1:≥10 is due to wild-type 
YF virus or due to 17D vaccine. A subanalysis of vaccinees with nonreactive PRNT at baseline showed a PRNT 
seropositivity rate after ten years similar to patients with reactive PRNT at baseline. Furthermore, originating 
from YF endemic countries or having reactive PRNT before first documented YFV were associated with a better 
immune response only in the short but not the longer term. Thus, even though we cannot exclude prior YFV in 
all participants the immune response of our whole population seems to be representative. 
Suppressed HIV RNA at baseline was the main predictor in our study for developing and maintaining protective 
immune response. Successful cART reduces immune activation, improves T-helper response, has been shown to 
ameliorate immune responses to other vaccines [25–28], and also reduces the incidence of opportunistic 
infections independently of the current CD4 cell count [29]. More than 90% of Swiss HIV-infected persons on 
cART remain suppressed over time [30]. In fact, all our patients with HIV RNA suppressed at baseline were 
virologically controlled at the ten-year follow-up determination of vaccine response (data not shown). Thus, 
HIV-infected patients mount a long-standing protective immune response to YFV up to at least ten years if they 
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are vaccinated while remaining on successful cART. Whether this immunity after a single primary dose of YFV 
is lifelong, as suggested by WHO for immunocompetent persons, still remains to be shown. However, even this 
WHO recommendation is controversial, in particular concerning travellers residing in non-YF-endemic countries 
[4–7]. Therefore, until further data are available a single booster after ten years seems to be adequate to 
restimulate the vaccine response in the event of new travel to a YF endemic region. If time allows, testing of YF 
PRNT before travel is also an option. 
The effect of suppressed HIV viral load on long-term YFV immunity seems to hold irrespective of age, sex, 
hepatitis coinfection, or region of origin. Neither the CD4 cell count nor CD4 cell nadir appears to have a major 
influence as long as it is in range observed in our population. In a Brazilian cross-sectional analysis, the 
CD4/CD8 ratio but not absolute CD4 cell count at the time of serological testing was positively associated with 
immune response to YF vaccine [24]. All the participants had undetectable plasma HIV RNA at the time of 
serological analysis. The CD4/CD8 ratio is a marker both of immune competence and of immune activation, and 
is known to increase and often even normalize with time on cART. 
Stored samples allowed longitudinal evaluation of serologic response. We are not aware of any other large study 
in HIV-infected patients analysing individual longitudinal data after YFV. We observed a few patients in whom 
the titre increased during follow-up even though a booster YFV was ruled out with certainty. This may be due to 
ongoing immune-reconstitution on cART or a cross-reaction after exposure to or vaccination against other 
flaviviruses or unspecific broad B-cell activation as seen after mononucleosis-like infections. Reactive PRNT 
before YFV was not statistically associated with higher titres over time (Table S1a-c). 
No deaths, or viscerotropic or neurological disease occurred following YFV in 187 patients that were vaccinated 
during prospective follow-up in SHCS. However, the number of vaccinees studied was not large enough to 
reliably assess small risks.  
 
Limitations 
The results of a retrospective study within a prospective cohort did not allow systematic determination of PRNT 
for all patients at precisely defined p.v. intervals Nevertheless, due to prospectively stored SHCS plasma 
samples this study provides a valuable longitudinal, individual follow-up of PRNTs. The majority of patients 
with PRNT determinations five or ten years p.v. also had had a PRNT determination within one year p.v. with a 
proportion of protective PRNT in the follow-up similar to the whole study population. 
 
Conclusion 
In this large cohort study HIV-infected patients' long-term immune response up to ten years to YFV is primarily 
dependent on the control of HIV replication at the time of vaccination. Vaccinees on successful cART had high 
levels of reactive PRNT and protective titres were maintained up to ten years. Our results point towards 
acceptable safety of YFV in HIV-infected individuals on cART. 
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Until further data on long-term immunity are available, we recommend that HIV-infected patients should be 
vaccinated against YF once their HIV RNA is suppressed and receive an YFV booster after ten years if they stay 
on uninterrupted successful cART to restimulate the vaccine response. However, HIV-infected persons who 
were vaccinated with replicating HIV should either have their PRNT measured or receive a booster YFV while 
on successful cART, irrespective of time elapsed since primary YFV. 
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 Table 1: Baseline and laboratory characteristics of HIV infected patients at time of first reported vaccination against yellow fever, Swiss HIV Cohort Study, 2013 
 
 
Characteristic     Participants with follow-up determination of yellow fever PRNT 
 
    Baseline 
 
Within first year 
n=201 
At 5 years 
n=122 
At 10 years 
n=63 
 All 
 
N=247 
PRNT 
1:<10 
n=99 
PRNT  
1:≥10 
n=83 
PRNT 
n.a. 
n=65 
PRNT 
1:<10 
n=10 
PRNT  
1:≥10 
n=191 
PRNT 1:<10 
n=17 
PRNT 1:≥10 
n=105 
PRNT 1:<10 
n=16 
PRNT 1:≥10 
n=47 
Age  (years) 
     Median (IQR) 
     Range 
 
38 (31-45) 
19-67 
 
 
38  (31-47) 
20-67 
 
 
40 (35-46) 
23-63 
 
 
32 (28-39) 
19-55 
 
 
33 (26-43) 
22-45 
 
 
39 (33-46) 
20-67 
 
33 (26-38) 
22-52 
 
 
37 (30-42) 
19-63 
 
 
31 (28-39) 
24-52 
 
 
33 (28-40) 
19-63 
 
Female sex 130 (53) 46 (47) 44 (53) 40 (62) 4 (40) 97 (51) 11 (65) 54 (51) 7 (44) 29 (62) 
Region of origin   
     Sub-Saharan Africa 
     Europe or North America 
     South America 
     Other 
 
135 (55) 
101 (41) 
8 (3) 
3 (1) 
 
50 (51) 
46 (47) 
3 (3) 
0 (0) 
 
53 (64) 
23 (23) 
5 (6) 
2 (2) 
 
32 (49)
#
 
32(49) 
 0 (0) 
1 (2) 
 
3 (30) 
7 (70) 
0 (0) 
0 (0) 
 
 
109 (57) 
71 (37) 
8 (4) 
3 (2) 
 
5 (29) 
11 (65) 
1 (6) 
0 (0) 
 
 
51 (49)
#
 
49 (47) 
 4 (4) 
1 (1) 
 
 
3 (19) 
13 (81) 
0 (0) 
0 (0) 
 
 
25 (53) 
22 (47) 
0 (0) 
0 (0) 
 
CDC HIV infection category 
     A 
     B 
     C 
 
153 (62) 
51 (21) 
43 (17) 
 
59 (60) 
20 (20) 
20 (20) 
 
41 (49) 
24 (29) 
18 (22) 
 
53 (82)# 
7 (11) 
5 (8) 
 
6 (60) 
4 (40) 
0 (0) 
 
110 (58) 
42 (22) 
39 (20) 
 
14 (82) 
2 (12) 
1 (6) 
 
62 (59) 
26 (25) 
17 (16) 
 
14 (88)
#
 
2 (13) 
0 (0) 
 
32 (68)
#
 
12 (26) 
3 (6) 
Chronic hepatitis B or C 
     Yes 
     Missing 
 
41 (19)** 
27 (11) 
 
 
18 (18)** 
0 (0) 
 
 
12 (15)** 
1 (1) 
 
 
11 (28)** 
26 (40) 
 
 
1 (10)** 
0 (0) 
 
 
36 (19) 
0 (0) 
 
3 (27)** 
6 (35) 
 
 
24(25)** 
10 (10) 
 
 
1 (10)** 
6 (38) 
 
 
9 (25)** 
11 (23) 
 
Smoking habits 
     Yes 
     Missing 
 
46 (26)** 
70 (28) 
 
26 (29)** 
10 (10) 
 
18 (23)** 
4 (5) 
 
2 (22)** 
56 (86) 
 
4 (57)** 
3 (30) 
 
42 (26) 
27 (14) 
 
2 (50)** 
13 (77) 
 
 
18 (25)** 
33 (31) 
 
 
3 (60)** 
11 (69) 
 
 
8 (38)** 
25 (55) 
 
Taking cART 
     Yes 
     Missing 
 
150 (82)** 
63 (26) 
 
 
65 (77)** 
15 (15) 
 
 
65 (83)** 
5 (6) 
 
 
20 (91)** 
43 (66) 
 
 
3 (60)** 
5 (50) 
 
 
131 (82) 
30 (16) 
 
 
2 (40)** 
12 (71) 
 
 
59 (78)** 
29 (28) 
 
 
2 (40)** 
11 (69) 
 
 
20 (75)** 
19 (40) 
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Note: Baseline= at time of first documented yellow fever vaccination, data are in no. (%) of patients unless otherwise indicated, n.a. = data not available, cART = combination antiretroviral therapy,  
YF = yellow fever, YFV= YF vaccination, 
#
Due to rounding, the overall percentage is over 100%. ** % is related to patients with yes/no.  
CD4 cell count* (cells/mm
3
)                    
     Median  
     IQR 
     Range 
     Missing 
CD4 cell strata*  (cells/mm
3
)
 
                     
     <200  
     200 – 349  
     350 – 499  
     ≥500  
 
536  
412-697 
11-1730 
21 (9) 
 
                                                    
11 (5)
#
 
25 (11) 
61 (27) 
130 (58) 
 
537  
418-760 
250-1730 
0 (0) 
 
                                    
0 (0) 
10 (10) 
32 (32) 
57 (58) 
 
585  
462-726 
11-1298 
0 (0) 
 
                                     
2 (2) 
6 (7) 
18 (22) 
57 (69) 
 
403  
263-630 
72-1110 
21 (32) 
 
                                    
9 (21)
#
 
9 (21) 
10 (23) 
16 (36) 
 
489 
281-576 
100-741 
0 (0) 
 
2 (20) 
2 (20) 
2 (20) 
4 (60) 
 
570 
423-728 
11-1730 
0 (0) 
 
 
5 (3)
#
 
20 (11) 
48 (25) 
118 (62) 
 
148  
100-451 
11-576 
6 (35) 
 
 
6 (56) 
1 (9) 
3 (27) 
1  (9) 
 
574 
424-728 
163-1730 
6 (6) 
 
 
2 (2) 
10 (10) 
25 (25) 
62 (63) 
 
 
476  
250-907 
100-983 
6 (38) 
 
 
2  (20) 
1 (10) 
3 (30)  
4 (40) 
 
532  
416-664 
148-1115 
9 (19) 
 
 
3  (8) 
5 (13) 
9 (24) 
21 (55) 
Nadir CD4 cell count  (cells/mm
3
)                      
     Median  
     IQR 
     Range 
     Missing  
 
 
 
240  
130-322 
2-829 
38 (15) 
 
 
250  
158-353 
3-829 
0 (0) 
 
 
204  
114-304 
2-745 
0 (0) 
 
 
225  
130-299 
33-713 
38 (59) 
 
 
409 
- 
114-576 
2 (20) 
 
 
241 
130-321 
2-829 
11 (6) 
 
 
210 
- 
30-576 
10 (59) 
 
 
266 
151-340 
2-829 
14 (13) 
 
 
487 
 
33-829 
7 (44) 
 
 
 
245 
146-321 
17-580 
15 (32) 
HIV-RNA level * <400  copies/ml 
     Yes 
     Missing measurements 
 
 
165 (83)** 
47 (19) 
 
 
76 (78)** 
1 (1) 
 
 
71 (87)** 
1 (1) 
 
 
18 (90)** 
45 (69) 
 
 
2 (25)** 
2 (20) 
 
 
148 (84)** 
14 (7) 
 
 
1 (20)** 
12 (71) 
 
 
68 (77)** 
17 (16) 
 
 
0 (0)** 
8 (50) 
 
 
24 (80)** 
17 (36) 
 
Number of YFV 
     First vaccination 
     Second vaccination 
     Third vaccination 
 
 
 
247 
27 
2  
    
 
  
 
 
 
 
  
 
 
 
 
 
First YFV vaccine type 
     Stamaril®) 
     Other 
     Unknown 
 
158 (64) 
15 (6) 
74 (30) 
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Table 2: Follow-up of plaque reduction neutralisation titre of HIV-infected patients with first 
reported vaccination against yellow fever, Swiss HIV Cohort Study, 2013 
 
Characteristic Before YFV 
n=182 
Within first year 
n=201 
At 5 years 
n=122 
At 10 years 
n=63 
YF PRNT  
     PRNT 1: ≥10 
     PRNT 1:<10 
 
83 (46) 
99 (54) 
 
191 (95) 
10 (5) 
 
105 (86) 
17 (14) 
 
47 (75) 
16 (25) 
95% CI for reactive 
PRNT (%) 
 
38-53 
 
91-98 
 
79-92 
 
62-85 
Reciprocal of PRNT 
quantification (1/x) 
     Median (IQR) 
     Range 
 
 
9 (6-23) 
0-181 
 
 
54 (30-105) 
0->320 
 
 
41 (16-77) 
0-226 
 
 
26 (8-66) 
0- >320 
Years between PRNT  
determination and YFV  
     Median (IQR) 
     Range 
 
 
-0.23 (-0.4- -0.06) 
-7.1- 0 
 
 
0.4 (0.25-0.5) 
0.09-1 
 
 
5.0 (4.8-5.1) 
4.0-5.7 
 
 
10.0 (9.8-10.2) 
9.5-11 
 
Subanalysis of PRNT in patients with nonreactive PRNT at baseline 
N 99 95 51 23 
YF PRNT  
     PRNT 1: ≥10 
     PRNT 1:<10 
 
0 (0) 
99 (100) 
 
88 (93) 
7 (7) 
 
48 (94) 
3 (6) 
 
17 (74) 
6 (26) 
95% CI for reactive 
PRNT (%) 
 
0-4
+
 
 
85-97 
 
84-99 
 
52-90 
Reciprocal of PRNT 
quantification (1/x) 
     Median (IQR) 
     Range 
 
 
6 (6-7) 
0-9 
 
 
50 (23-92) 
0->320 
 
 
41 (26-64) 
5-140 
 
 
31 (8-101) 
6- 193 
Subanalysis of PRNT in patients with reactive PRNT at baseline 
N 83 81 33 12 
YF PRNT  
     PRNT 1: ≥10 
     PRNT 1:<10 
 
83 (100) 
0 (0) 
 
81 (100) 
0 (0) 
 
31 (94) 
2 (6) 
 
11 (92) 
1 (8) 
95% CI for reactive 
PRNT (%) 
 
96-100
+
 
 
96-100
+
 
 
80-99 
 
62-100 
Reciprocal of PRNT 
quantification (1/x) 
     Median (IQR) 
     Range 
 
 
24 (13-43) 
10-181 
 
 
81 (42-170) 
10->320 
 
 
51 (26-105) 
5-226 
 
 
51 (28-121) 
6- >320 
Subanalysis of PRNT in patients with HIV RNA <400 cop/mL at baseline (all) 
N 147 150 69 24 
YF PRNT  
     PRNT 1: ≥10 
     PRNT 1:<10 
 
71 (48) 
76 (52) 
 
148 (99) 
2 (1) 
 
68 (99) 
1 (2) 
 
24 (100) 
0 (0) 
95% CI for reactive 
PRNT (%) 
 
40-57 
 
95-99.8 
 
92-100 
 
86-100
+
 
Reciprocal of PRNT 
quantification (1/x) 
     Median (IQR) 
     Range 
 
 
9 (6-7) 
0-181 
 
 
150 (72-126) 
5->320 
 
 
50 (35-100) 
6-226 
 
 
82 (30-131) 
12>320 
Subanalysis of PRNT in patients with nonreactive PRNT and with HIV RNA <400 cop/mL at baseline 
N 76 73 34 13 
YF PRNT  
     PRNT 1: ≥10 
     PRNT 1:<10 
 
0 (0) 
76 (100) 
 
72 (99) 
1 (1) 
 
33 (97) 
1 (3) 
 
13 (100) 
0 (0) 
95% CI for reactive 
PRNT (%) 
 
0-5
+
 
 
93-100 
 
85-99.9 
 
75-100
+
 
Reciprocal of PRNT 
quantification (1/x) 
     Median (IQR) 
     Range 
 
 
6 (6-7) 
0-9 
 
 
61 (39-98) 
5->320 
 
 
48 (35-85) 
6-140 
 
 
93 (65-140) 
25- 193 
Subanalysis of PRNT in patients with reactive PRNT and with HIV RNA <400 cop/mL at baseline 
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N 71 69 27 9 
YF PRNT  
     PRNT 1: ≥10 
     PRNT 1:<10 
 
71 (100) 
0 (0) 
 
69 (100) 
0 (0) 
 
27 (100) 
0 (0) 
 
9 (100) 
0 (0) 
95% CI for reactive 
PRNT (%) 
 
95-100
+
 
 
95-100
+
 
 
87-100
+
 
 
66-100
+
 
Reciprocal of PRNT 
quantification (1/x) 
     Median (IQR) 
     Range 
 
 
24 (14-43) 
10-181 
 
 
97 (44-174) 
13->320 
 
 
57 (31-106) 
16-226 
 
 
59 (35-108) 
23- >320 
Note: Data are in no. (%) of patients unless otherwise indicated. N= number of analysed patients. IQR= interquartile range, CI = 
confidence interval, YF = yellow fever, YFV = YF vaccination, PRNT = plaque reduction neutralisation titre; 
+
one-sided 97,5% 
confidence interval. 
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Table 3: Factors associated with reactive plaque reduction neutralisation titre after a) one, b) 
five, and c) ten years following first reported vaccination against yellow fever among HIV 
infected patients, Swiss HIV Cohort Study, 2013 
a) Within one year following yellow fever vaccination 
    
 UNIVARIABLE  MULTIVARIABLE ANALYSIS 
Patient characteristics N RP (95% CI) p  N RP (95% CI) P 
      175    
Age (per 10 years increase) 201 1.03 1.0-1.07 0.048   1.03 0.99-1.06 0.1 
Female sex  201 1.02 0.96-1.09 0.5   1.0 0.96-1.04 1.0 
Smoking habits 171 0.94 0.85-1.03 0.2      
Chronic hepatitis B or C 201 1.03 0.96-1.10 0.4   1.04 1.0-1.08 0.03 
CDC classification (A vs. B/C) 201 1.01 0.94-1.07 0.9      
Originating from YF endemic  
country 
201 1.07 0.99-1.15 0.08   1.07 1.0-1.14 0.055 
Taking cART 166 1.04 0.95-1.15 0.4      
          
CD4 cell nadir (square rooted) 188 1.01 0.99-1.0 0.07   1.0 1.0-1.01 0.4 
CD4 cell count (square rooted)  201 1.01 1.0-1.01 0.07   1.0 1.0-1.01 0.2 
HIV RNA level (<400 copies/ml 
versus ≥400 copies/ml) 
185 1.19 1.02-1.39 0.03   1.19 1.02-1.38 0.03 
Nonreactive PRNT before YFV 176 0.93 0.88-0.98 0.01   0.95 0.92-0.99 0.02 
Note:  Analysis by Poisson regression of the association of reactive (PRNT1:≥10) to nonreactive plaque reduction neutralisation titre (PRNT 1:<10) within one 
year following yellow fever vaccination with baseline characteristics. N= number of investigated patients; RP= relative proportion, CI= confidence interval; CDC 
classification = CDC category for HIV infection, cART= combination antiretroviral therapy. YF= Yellow fever; YFV = YFV vaccination, PRNT= plaque reduction 
neutralisation titre 
 
b) Five years following yellow fever vaccination 
    
 UNIVARIABLE  MULTIVARIABLE ANALYSIS 
Patient characteristics N RP (95% CI) P  N RP (95% CI) P 
      82    
Age (per 10 years increase) 122 1.07 1.0-1.14 0.07   1.02 0.97-1.07 0.5 
Female sex  122 0.93 0.81-1.07 0.3   1.02 0.96-1.07 0.6 
Smoking habits 76 0.93 0.80-1.09 0.4      
Chronic hepatitis B or C 106 1.0 0.85-1.15 0.9   1.04 0.98-1.09 0.2 
CDC classification (A vs. B/C) 122 1.15 1.0-1.31 0.04      
Originating from YF endemic  122 1.14 0.98-1.31 0.08   1.05 0.98-1.14 0.2 
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country 
Taking cART 81 1.14 0.94-1.38 0.2      
          
CD4 cell nadir (square rooted) 98 1.0 0.99-1.01 0.8   1.0 0.99-1.00 0.3 
CD4 cell count (square rooted)  110 1.03 1.01-1.05 <0.001   1.01 1.00-1.02 0.1 
HIV RNA level (<400 copies/ml 
versus ≥400 copies/ml) 
93 1.18 1.0-1.42 0.07   1.09 0.94-1.26 0.3 
Nonreactive PRNT before YFV 84 1.0 0.90-1.12 1.0   1.0 0.91-1.10 1.0 
Note:  Analysis by Poisson regression of the association of reactive (PRNT1:≥10) to nonreactive plaque  reduction neutralisation titre (PRNT 1:<10)  after 5 
years following yellow fever vaccination with baseline characteristics. N= number of investigated patients; RP= relative proportion; CI= confidence interval; CDC 
classification = CDC category for HIV infection, cART= combination antiretroviral therapy, YF= Yellow fever; YFV = YFV vaccination, PRNT= plaque  reduction 
eutralisation titre 
 
b) 10 years following yellow fever vaccination 
     
  UNIVARIABLE  MULTIVARIABLE ANALYSIS 
Patient characteristics N RP (95% CI) P  N RP (95% CI) P 
      34    
Age (per 10 years increase) 63 0.99 0.83-1.19 0.9   0.87 0.73-1.03 0.1 
Female sex  63 1.21 0.88-1.65 0.2   0.89 0.62-1.29 0.5 
Smoking habits 26 0.84 0.55-1.28 0.4      
Chronic hepatitis B or C 46 1.2 0.90-1.59 0.2   0.90 0.71-1.14 0.4 
CDC classification (A vs. B/C) 63 1.27 0.98-1.65 0.07      
Originating from YF endemic  
country 
63 1.42 1.07.-1.90 0.02   0.85 0.56-1.29 0.5 
Taking cART 33 1.30 0.85-2.01 0.2      
          
CD4 cell nadir 41 0.97 0.93-1.0 0.05   0.97 0.94-1.0 0.07 
CD4 cell count (square rooted)  48 1.01 0.97-1.04 0.7   0.99 0.95-1.04 0.8 
HIV-RNA level (<400 copies/ml 
versus ≥400 copies/ml) 
38 2.33 1.26-4.31 0.01   2.07 1.19-3.6 0.01 
Nonreactive PRNT before YFV 35 0.81 0.60-1.09 0.2   0.85 0.63-1.14 0.3 
Note:  Analysis by Poisson regression of the association of reactive (PRNT1:≥10) to nonreactive  plaque reduction neutralisation titre (PRNT 1:<10)  after 10 years following yellow fever 
vaccination with baseline characteristics. N= number of investigated patients; RP = relative proportion; CI= confidence interval; CDC classification = CDC category for HIV infection, cART = 
combination antiretroviral therapy,  YF = Yellow fever; YFV = YFV vaccination, PRNT = plaque reduction neutralisation titre 
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Figure Legend 
 
Figure 1: Study design, HIV-infected patients with first documented yellow fever vaccination, 
Swiss HIV Cohort Study, 2013 
 
Note: PRNT= plaque reduction neutralisation titre, YF= yellow fever, YFV= yellow fever vaccination, 
n= number of patients investigated 
 
Figure 2: Proportion of HIV-infected patients with reactive plaque reduction neutralisation titre 
within one year, after five, and ten years following yellow fever vaccination, Swiss HIV Cohort 
Study, 2013 
 
Note: Percentage and numbers of patients are shown with reactive (black) and nonreactive (gray) 
plaque reduction neutralisation titre (PRNT). Numbers in chart indicate the number of subjects 
analysed. YFV= yellow fever vaccination 
 
Figure 3: Boxplots of reciprocal plaque reduction neutralisation titre within one, after five, and 
ten years following yellow fever vaccination, Swiss HIV Cohort Study, 2013 
 
Note: Black line in the grey shaded box shows the median of the values. Lower (upper) end of the box 
shows the 25
th
 and 75
th
 percentile of the values, and single dots show outliers defined as values 
whose distance to the upper end of the box is larger than 1.5 times the height of the box. PRNT= 
plaque reduction neutralisation titre, YFV= yellow fever vaccination. 
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